Citigroup Maintains Neutral on Prime Medicine, Lowers Price Target to $4.25
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $5 to $4.25.
Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $5 to $4.25.